FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?

Josué de Moraes; Timothy G Geary

doi:10.1016/j.pt.2020.04.005

FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?

Trends Parasitol. 2020 Jul;36(7):573-575. doi: 10.1016/j.pt.2020.04.005. Epub 2020 May 6.

Authors

Josué de Moraes¹, Timothy G Geary²

Affiliations

¹ Research Center for Neglected Diseases, Guarulhos University, Guarulhos, SP, Brazil. Electronic address: moraesnpdn@gmail.com.
² Institute of Parasitology, McGill University, Montreal, QC, Canada; School of Biological Sciences, Queen's University, Belfast, UK.

PMID: 32387059
DOI: 10.1016/j.pt.2020.04.005

Abstract

Diseases caused by helminth infections affect more than a quarter of the population of the world, but the therapeutic arsenal is limited. The approval of moxidectin in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against diseases of poverty, such as helminthiases.

Keywords: FDA; helminthiasis; moxidectin; triclabendazole.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anthelmintics / therapeutic use
Drug Approval*
Helminthiasis / drug therapy*
Humans
Macrolides / therapeutic use*
Triclabendazole / therapeutic use*
United States
United States Food and Drug Administration

Substances

Anthelmintics
Macrolides
Triclabendazole
moxidectin